(Reuters) - Pfizer Inc's experimental breast cancer drug in a clinical trial nearly doubled the amount of time patients lived without their disease getting worse, but overall survival was not yet shown to be statistically significant, researchers said.
via Reuters: Health News Read More Here..
No comments:
Post a Comment